CA2625642C - Prolinamide derivatives as sodium channel modulators - Google Patents

Prolinamide derivatives as sodium channel modulators Download PDF

Info

Publication number
CA2625642C
CA2625642C CA2625642A CA2625642A CA2625642C CA 2625642 C CA2625642 C CA 2625642C CA 2625642 A CA2625642 A CA 2625642A CA 2625642 A CA2625642 A CA 2625642A CA 2625642 C CA2625642 C CA 2625642C
Authority
CA
Canada
Prior art keywords
disorder
compound
disease
compounds
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2625642A
Other languages
English (en)
French (fr)
Other versions
CA2625642A1 (en
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2625642A1 publication Critical patent/CA2625642A1/en
Application granted granted Critical
Publication of CA2625642C publication Critical patent/CA2625642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CA2625642A 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators Active CA2625642C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0520581.0 2005-10-10
GB0523045.3 2005-11-11
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900.2 2006-02-27
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
GB0618336.2 2006-09-18
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (2)

Publication Number Publication Date
CA2625642A1 CA2625642A1 (en) 2007-04-19
CA2625642C true CA2625642C (en) 2013-12-24

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2625642A Active CA2625642C (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Country Status (20)

Country Link
US (2) US7655693B2 (https=)
EP (1) EP1934177B8 (https=)
JP (1) JP5139305B2 (https=)
KR (1) KR101282464B1 (https=)
AR (1) AR056575A1 (https=)
AT (1) ATE556049T1 (https=)
AU (1) AU2006301470B2 (https=)
BR (1) BRPI0616944B8 (https=)
CA (1) CA2625642C (https=)
CR (1) CR9898A (https=)
EA (1) EA015736B1 (https=)
ES (1) ES2387405T3 (https=)
IL (1) IL192627A0 (https=)
MA (1) MA29817B1 (https=)
NO (1) NO20082145L (https=)
NZ (1) NZ567051A (https=)
PE (1) PE20070592A1 (https=)
PL (1) PL1934177T3 (https=)
TW (1) TW200730494A (https=)
WO (1) WO2007042239A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) * 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
JP5855000B2 (ja) * 2009-09-14 2016-02-09 クオンベルゲンセ プハルマセウトイカルス リミテッド α−カルボキサミド誘導体の製造方法
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP3110794A1 (en) 2014-02-27 2017-01-04 Merck Patent GmbH Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規投薬レジメン
MX2019013758A (es) * 2017-05-19 2020-07-20 Biogen Ma Inc Formas cristalinas novedosas.
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
CA3077088A1 (en) 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives
KR20210002472A (ko) * 2018-04-16 2021-01-08 바이오젠 엠에이 인코포레이티드 신경병증성 통증을 치료하는 방법
MX2021012421A (es) * 2019-04-10 2022-02-10 Biogen Inc Procesos para preparar derivados de pirrolidina alfa-carboxamida.
AU2020271856A1 (en) * 2019-04-10 2021-12-02 Biogen Ma Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
US12544385B2 (en) 2020-01-30 2026-02-10 Mohammad JAVED Combination drug therapies for CNS disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
CA2368631A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
EP1618099A4 (en) 2003-04-18 2008-07-16 Merck & Co Inc BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
EP1877381A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US7858786B2 (en) 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20080280969A1 (en) 2008-11-13
NO20082145L (no) 2008-05-07
BRPI0616944B1 (pt) 2020-04-14
WO2007042239A1 (en) 2007-04-19
EP1934177A1 (en) 2008-06-25
EP1934177B1 (en) 2012-05-02
PE20070592A1 (es) 2007-06-23
IL192627A0 (en) 2011-08-01
NZ567051A (en) 2011-03-31
ATE556049T1 (de) 2012-05-15
JP2009511519A (ja) 2009-03-19
JP5139305B2 (ja) 2013-02-06
EA015736B1 (ru) 2011-10-31
PL1934177T3 (pl) 2013-03-29
EP1934177B8 (en) 2012-09-05
ES2387405T3 (es) 2012-09-21
AU2006301470A1 (en) 2007-04-19
BRPI0616944B8 (pt) 2021-05-25
US8153681B2 (en) 2012-04-10
EA200801054A1 (ru) 2008-08-29
KR101282464B1 (ko) 2013-07-04
CR9898A (es) 2008-07-29
MA29817B1 (fr) 2008-09-01
AU2006301470B2 (en) 2012-06-14
CA2625642A1 (en) 2007-04-19
BRPI0616944A2 (pt) 2011-07-05
AR056575A1 (es) 2007-10-10
US20100105754A1 (en) 2010-04-29
TW200730494A (en) 2007-08-16
KR20080059296A (ko) 2008-06-26
US7655693B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
US8153681B2 (en) Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide
US8153623B2 (en) Compounds
US20100130583A1 (en) Prolinamide derivatives as modulators of voltage-gated sodium channels
US7855218B2 (en) Compounds
US8143306B2 (en) Methods of treating bipolar disorders
CN101326163B (zh) 作为钠通道调控剂的脯氨酰胺衍生物
EP1137412A2 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CN101326162A (zh) 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250408